Last reviewed · How we verify

NCT06100510

PFA 100 Evaluation and Reference Interval HOACNY

ENROLLING BY INVITATION Phase 4 Last updated 3 October 2024
What this trial tests

Phase 4 trial testing Aspirin 325mg in Effect of Drug in 40 participants. Enrolling by invitation.

Timeline
19 February 2024
Primary endpoint
10 October 2024
10 October 2024

Quick facts

Lead sponsorHematology Oncology Associates of Central New York
PhasePhase 4
StatusENROLLING BY INVITATION
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposescreening
Enrollment40
Start date19 February 2024
Primary completion10 October 2024
Estimated completion10 October 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Hematology Oncology Associates of Central New York

Who can join

18 and older, any sex, with Effect of Drug. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research is to evaluate instrument functionality and develop a reference range of normal data by healthy volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Aspirin 325mg

Trials testing the same drug.

Other recruiting trials for Effect of Drug

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06100510.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing